TherapeuticsMD (TXMD) Projected to Post Earnings on Monday

TherapeuticsMD (NASDAQ:TXMD) is expected to be releasing its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect the company to post earnings of ($6.1250) per share and revenue of $19.7680 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 18, 2026 at 4:00 PM ET.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13. TherapeuticsMD had a return on equity of 0.32% and a net margin of 5.34%.The business had revenue of $0.72 million during the quarter, compared to the consensus estimate of $19.77 million.

TherapeuticsMD Stock Performance

Shares of NASDAQ:TXMD opened at $2.07 on Monday. The firm has a market cap of $23.95 million, a price-to-earnings ratio of 34.50 and a beta of 0.61. The stock’s 50-day moving average price is $2.04 and its two-hundred day moving average price is $2.14. TherapeuticsMD has a 12-month low of $0.99 and a 12-month high of $2.95.

Institutional Trading of TherapeuticsMD

An institutional investor recently raised its stake in TherapeuticsMD stock. Citadel Advisors LLC increased its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 34,273 shares of the company’s stock after buying an additional 19,073 shares during the quarter. Citadel Advisors LLC owned about 0.30% of TherapeuticsMD worth $36,000 as of its most recent filing with the Securities and Exchange Commission. 30.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of TherapeuticsMD in a report on Thursday, July 2nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, TherapeuticsMD currently has a consensus rating of “Sell”.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.